Diabetic macular oedema (DMO)

Diabetic macular oedema (DMO) is the most common cause of sight loss or even blindness in people with diabetes. Sometimes, leaky vessels can cause fluid to build up in the macula, at the centre of the retina. This swelling is known as diabetic macular oedema.

Showing all 4 results

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
1
Classes of molecule​s
Isotypes
Expiry Date
CoA
Filters Sort results
Reset Apply

Product
Batch

Antigen
Molecular Class
Drug Brand
Product Concentration
CoA
Quantity per vial
Storage Temperature
Expiry Date
Price from
PIGF
,
VEGF-A
Fusion protein
Eylea®
40 mg/mL
0,8 mg
-80°C
11/2021
548,10 
view product
Max: 1
Min: 1
Step: 1
PIGF
,
VEGF-A
Fusion protein
Eylea®
40 mg/mL
0,8 mg
-80°C
02/2025
1.011,00 
view product
Max: 1
Min: 1
Step: 1
VEGF
Biosimilar
,
Monoclonal Antibody
Ximluci®
10 mg/mL
0,21 mg
tba
tba
680,00 
view product
Max: 10
Min: 5
Step: 1
VEGF
Monoclonal Antibody
Byooviz®
10 mg/mL
0,21 mg
tba
tba
621,00 
view product
Max: 10
Min: 5
Step: 1

Not looking for Diabetic macular oedema (DMO)?

Search our therapeutic molecules product database